Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from RedHill Biopharma ( (RDHL) ) is now available.
On December 19, 2025, RedHill Biopharma entered into a Standby Equity Purchase Agreement with YA II PN, Ltd., giving the company, over a 36‑month period from that date, the discretionary right to sell up to $25 million of its ADSs to the investor, subject to trading‑volume, pricing and ownership caps, including a 9.99% beneficial ownership limit. As part of the initial funding step under this structure, RedHill on the same date issued 386,593 ADSs and a pre‑funded warrant for 590,446 ADSs for gross proceeds of $1 million, agreed to pay a 2% commitment fee partly in ADSs (including 122,130 ADSs already issued), and committed to registering all related ADS resales with the SEC, a move that provides a flexible but potentially dilutive equity financing mechanism to support the company’s capital needs.
The most recent analyst rating on (RDHL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.
Spark’s Take on RDHL Stock
According to Spark, TipRanks’ AI Analyst, RDHL is a Underperform.
RedHill Biopharma’s overall stock score is primarily influenced by its challenging financial performance, characterized by significant losses and high leverage. The technical analysis suggests a bearish trend, further impacting the score. The absence of valuation metrics and earnings call data limits a comprehensive assessment, resulting in a low overall score.
To see Spark’s full report on RDHL stock, click here.
More about RedHill Biopharma
RedHill Biopharma Ltd. is an Israeli biopharmaceutical company whose American Depositary Shares (ADSs), each representing 10,000 ordinary shares, trade on the Nasdaq Stock Market under the symbol RDHL. The company operates in the biotech/pharmaceutical industry, focusing on the development and commercialization of specialty drugs, and raises capital on U.S. markets via ADS structures to support its operations and pipeline.
Average Trading Volume: 1,854,463
Technical Sentiment Signal: Sell
Current Market Cap: $5.36M
For a thorough assessment of RDHL stock, go to TipRanks’ Stock Analysis page.